RhoA Y42C inhibitor (Revere Pharmaceuticals)

N/A

Report date: 2025/04/01 16:19:36
NME

Base Information

Drug NameRhoA Y42C inhibitor (Revere Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho GTP-binding proteins inhibitors
TargetsRho GTP-binding proteins
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRevere Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRevere Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A